Salute e Benessere

Carterra Ships Its First Ultra Biosensor Platform and Finishes 2024 with…

Carterra's latest instrument enables high-throughput small and large-molecule characterization in traditional and AI-driven workflows XTsystems.The Ultra shipment was the capstone on a record year for Carterra revenues as well as exceptional, double-digit growth. “We understand that spending and investment in drug discovery technologies—especially capital equipment like ours—has been challenged the last couple of years,” observes Tim Germann, Carterra's Chief Commercial Officer...
Nasdaq GlobeNewswire
07/01/2025

GORTEC Announces New Trial Success for Head and Neck Cancer Treatment

"This is the first time in decades where a therapy demonstrated superiority over standard of care cisplatin-radiotherapy in high-risk patients with LA-SCCHN" said Prof Jean Bourhis, Principal Investigator of the study and Medical Director of the GORTEC. "This is the first time in decades where a therapy demonstrated superiority over standard of care cisplatin-radiotherapy in high-risk patients with LA-SCCHN " said ProfJean Bourhis, Principal Investigator of the study and…
PR Newswire
07/01/2025

Eyebright Medical Receives NMPA Class III Certificate for its Phakic Intraocular…

Constructed from an advanced balanced acrylic material, the Loong Crystal PR incorporates a zero spherical aberration design with a large optical zone and a double concave stable arch height structure. Upon implantation, it serves as a refractive element, significantly improving visual acuity while delivering high-quality postoperative results. This innovative design not only boosts optical performance but also elevates the overall visual experience, meeting the high expectations of patients for…
PR Newswire
07/01/2025

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating…

Key Results Key Results "Historically, paclitaxel-coated balloon angioplasty has been the mainstay therapy for PAD, particularly in the femoropopliteal vascular segment, and is based on the 'leaving nothing behind' principle. However, safety concerns remain, so that emerging evidence supports the exploration of sirolimus as alternative drug option in the treatment of PAD. With the SIRONA RCT showing sirolimus to be as effective as paclitaxel, physicians may soon have more personalized...
PR Newswire
07/01/2025

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT 2024

Sales in Zinzino's sales markets increased by 34% in the fourth quarter of 2024 compared with the same period last year and amounted to SEK 683.0 (509.1) million. Total revenue in the Group increased by 34% in the fourth quarter and amounted to SEK 706.1 (527.9) million. Sales in Zinzino's sales markets increased by 34% in the fourth quarter of 2024 compared with the same period last year and amounted toSEK 683.0(509.1) million. Total revenue in the Group increased by 34% in the fourth...
PR Newswire
07/01/2025

Global Recognition for Güven Hospital as a Leading Destination for International…

"We are honored to achieve GHA Accreditation," said Ms. Banu Küçükel, President of Güven Health Group. "This prestigious recognition underscores our unwavering commitment to patient safety, quality, and an exceptional international patient experience. The GHA accreditation process was not just an assessment but a highly consultative journey that offered invaluable insights and actionable solutions tailored to our needs. The expertise and guidance provided by the GHA team have…
PR Newswire
07/01/2025

ECOVACS Robotic Vacuum Cleaner DEEBOT X8 with OZMO ROLLER Technology: A Leap…

As the world's top brand in home service robotics, ECOVACS continues to drive the industry forward with its unwavering commitment to technological advancement. David Cheng Qian, Vice Chairman of ECOVACS Group and CEO of ECOVACS ROBOTICS, emphasized the company's strategy: "Our latest innovations not only underscore ECOVACS' leadership but also reflect our dedication to pioneering robotics solutions that anticipate and meet evolving consumer needs. We remain steadfast in our mission to…
PR Newswire
07/01/2025

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and…

The aXess EU pivotal trial is a prospective study investigating the patency, safety, and performance of aXess in adult patients with end-stage renal disease requiring vascular access to start or maintain hemodialysis therapy. A total of 120 patients have been recruited across 22 centers in nine countries across Europe. This trial follows outstanding 12-month data from the first in human EU trial, which demonstrated a significant improvement in performance compared to current hemodialysis…
PR Newswire
07/01/2025

Neuraxpharm to further grow branded business with the acquisition of two leading…

Neuraxpharm has acquired these products in most markets outside the US^. Provigil's main market is Europe, with significant sales in France, Spain and Italy. Nuvigil is present in international markets with significant sales in Australia and Mexico. Both Provigil and Nuvigil are orally administered CNS stimulants indicated to improve wakefulness and reduce Excessive Daytime Sleepiness (EDS) in adult patients with narcolepsy, both with and without cataplexy. Neuraxpharm has acquired these...
PR Newswire
07/01/2025

Vesper Bio initiates Phase Ib/IIa proof of concept study of VES001 in…

Mads Fuglsang Kjølby, Co-Founder and interim Chief Medical Officer at Vesper Bio, said: "The aim of this study is to further demonstrate the safety and tolerability of VES001 and confirm whether VES001 has a positive effect on progranulin levels in the cerebrospinal fluid and blood plasma of these patients. Progranulin is vital for maintaining neuronal health, however, progranulin levels in asymptomatic people with GRN mutations are typically half that of people without such mutations…
PR Newswire
07/01/2025

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 -…

Joerg Holenz, BIAL´s Chief Scientific Officer, comments: "The first patient out in the ACTIVATE study marks a pivotal milestone in the development of BIA 28-6156, as well as for our ambition to create transformative value for people living with neurodegenerative diseases. We are confident that our medicine has the potential to become a groundbreaking, novel treatment for patients with a confirmed diagnosis of GBA-PD. BIA 28-6156 offers a specific, potentially disease-modifying mechanism of…
PR Newswire
07/01/2025

Merck launches first-to-market, cyber-physical trust platform to tackle issues…

The M-Trust™ platform enables organizations to improve product quality and authenticity by immutably linking the physical and digital worlds. Powered by advanced Web 3.0 technology, the new offering supports the creation of digital twins for enhanced product security and the digitization of quality control processes. The M-Trust™ platform enables organizations to improve product quality and authenticity by immutably linking the physical and digital worlds. Powered by advanced Web 3.0...
PR Newswire
07/01/2025

Orion's collaboration partner Bayer submits application in China for third…

ORION CORPORATIONINVESTOR NEWS7 JANUARY 2025 at 9:00 EET Orion's collaboration partner Bayer submits application in China for third indication of darolutamide Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation...
Nasdaq GlobeNewswire
07/01/2025

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE.THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.For immediate release ...
Nasdaq GlobeNewswire
07/01/2025

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung…

The trial is designed to study BerGenBio's bemcentinib in combination with pacritinib, which is a JAK2 inhibitor indicated for treatment of the bone marrow disorder myelofibrosis in patients with platelet counts below 50 x 109/L. It works by blocking certain growth factors and cytokines. Pacritinib is marketed in the United States as VONJO® and owned by Swedish Orphan Biovitrum AB (Sobi®) (STO: SOBI), a specialized international biopharmaceutical company. Bemcentinib is a first-in-class…
PR Newswire
07/01/2025

Fagron strengthens its market positioning with the acquisitions of CareFirst in…

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 7 Jan 2025 – 7AM CET Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in BrazilFagron, the leading global player in pharmaceutical compounding is pleased to announce the signing of two strategic acquisitions: CareFirst Specialty Pharmacy in North America and Injeplast in Brazil. These acquisitions underscore Fagron's commitment to expanding across our key...
Nasdaq GlobeNewswire
07/01/2025

Press release: Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment…

Six Month Data from alfapump® Pivotal POSEIDON Studyin Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published inAmerican Journal of Gastroenterologyalfapump® system is effective in controlling ascites in decompensated cirrhosis with recurrent or refractory ascites by reducing or even eliminating the need for therapeutic paracentesis 1 Reduction was associated with a significant improvement in quality of life 1,2 10 additional good health...
Nasdaq GlobeNewswire
07/01/2025

Norgine submits Marketing Authorisation Application to the European Medicines…

This milestone further supports Norgine's efforts to give patients access to eflornithine and bring a further treatment option in the field of paediatric oncology. This milestone further supports Norgine's efforts to give patients access to eflornithine and bring a further treatment option in the field of paediatric oncology. Norgine and USWM, LLC (dba US WorldMeds), aKentucky -based specialty pharmaceutical company, have an exclusive licensing agreement by which Norgine will register and...
PR Newswire
07/01/2025

Amazfit Announces the Active 2; the Ultimate Everyday Smartwatch for Active and…

Stylish Design Meets Competitive Advantages Stylish Design Meets Competitive Advantages Along with a body crafted from stainless steel, the Amazfit Active 2 boasts a round 1.32-inch high-definition AMOLED display that can reach a peak brightness of 2,000 nits, ensuring that users can see their exercise data and maps even under bright sunlight. Consumers can choose from two models when purchasing: apremium versionpriced at$129.99that features a black genuine leather strap and a...
PR Newswire
07/01/2025

Idiopathic Inflammatory Myositis Market Predicted to Show Positive Growth at a…

Key Takeaways from the Idiopathic Inflammatory Myositis Market Report Key Takeaways from the Idiopathic Inflammatory Myositis Market Report Discover which therapies are expected to grab the major idiopathic inflammatory myositis market share @ Idiopathic Inflammatory Myositis Market Report Idiopathic Inflammatory Myositis Overview Idiopathic inflammatory myositis (IIM) is a rare autoimmune disorder that leads to muscle inflammation, causing muscle weakness, and in some cases, skin rashes...
PR Newswire
06/01/2025

Active Pharmaceutical Ingredients: Global Market Trends and Innovations

This report comprehensively analyzes the global active pharmaceutical ingredients (API) market in order to help readers evaluate the market landscape, develop growth strategies, and assess their market position. BCC Research estimates the API market size for 2023, with forecasts through 2029. The analysis focuses on API demand across regions and countries, clearly understanding consumption trends rather than production output. This report comprehensively analyzes the global active...
PR Newswire
06/01/2025

Vitestro Appoints Bob Gerberich as Chief Commercial Officer for North America

"We are thrilled to welcome Bob to the Vitestro team," said Toon Overbeeke, CEO and co-founder of Vitestro. "Bob's proven track record of launching innovative technologies and building high-growth businesses makes him the ideal leader to drive our U.S. commercialization. His expertise and leadership will be instrumental in bringing our autonomous robotic phlebotomy device to market and redefining the global standard for blood drawing." "We are thrilled to welcome Bob to…
PR Newswire
06/01/2025

Myant Acquires mmHg Inc. To Enhance Precision Medicine for Cardiovascular Care

mmHg's platform focuses on delivering efficient, guideline-concordant care for managing cardiovascular health, particularly in remote settings. Healthcare providers gain the capability to remotely track and analyze blood pressure and a spectrum of vital cardiovascular indicators through its innovative software. By aligning patient data with clinical best practices, mmHg enhances decision-making precision, driving timely and accurate interventions. Esteemed institutions across North America, such…
PR Newswire
06/01/2025

Medical Coatings Market to Hit USD 1419 Million by 2030: Key Trends in…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-17E9136/Global_Medical_Coatings_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-17E9136/Global_Medical_Coatings_Market Major Factors Driving the Growth of Medical Coatings Market: The Medical Coatings market is poised for substantial growth, driven by the increasing demand for advanced medical devices and the continuous innovation in coating technologies. The rising...
PR Newswire
06/01/2025
Altri  Comunicati